The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | An update on the RESTORE trial: expansion cohort data on elritercept plus ruxolitinib in MF
Ciro Rinaldi, MD, PhD, Lincoln County Hospital, Lincoln, UK, provides an update on the data from the expansion cohort of the RESTORE trial (NCT05037760), highlighting that patients with myelofibrosis (MF) receiving elritercept-ruxolitinib combination therapy maintained a transfusion response, with a consistent increase in hemoglobin levels and no drop-off from the patient perspective. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
